Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer
Sponsor: NCIC Clinical Trials Group
Listed as NCT00354302, this PHASE3 trial focuses on Breast Cancer and Osteoporosis and remains completed. Sponsored by NCIC Clinical Trials Group, it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2019 — May 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NCIC Clinical Trials Group
- National Cancer Institute (NCI)
- North Central Cancer Treatment Group
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Cambridge, Canada , Greenfield Park, Canada , Moncton, Canada , Québec, Canada , Regina, Canada , Saint John, Canada , Sault Ste. Marie, Canada , Thunder Bay, Canada , Toronto, Canada , Vancouver, Canada and 1 more location